How Wegovy Affects ALT: What Semaglutide 2.4 mg Does to Liver Enzymes

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly injectable GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with obesity, or overweight with a weight-related condition. It is the same molecule as Ozempic (semaglutide 2.0 mg, approved for type 2 diabetes) at a higher dose. Liver enzyme change, specifically ALT, is not part of Wegovy's approved indication. It is a downstream metabolic effect observed in trials designed primarily to measure weight loss and, in a separate trial program, liver histology in MASH.

The direct answer

Semaglutide 2.4 mg lowers ALT in most people who lose weight on it, through reduced liver fat and possibly through direct effects of GLP-1 receptor signaling on hepatic lipid metabolism. This is established at the level of trial evidence in the STEP program (weight loss) and a dedicated phase 2 MASH trial (histology and enzymes), not as an FDA-labeled hepatic indication. What is not established from the sources available for this review is a precise, generalizable percentage ALT change for the average Wegovy user. Readers and clinicians should treat specific numbers with caution until checked against the primary trial data, and should not use ALT trends alone to decide fibrosis status, since ALT can normalize while fibrosis persists.

What the trials actually measured

STEP-1 (N=1,961) was designed around body weight as the primary endpoint. Participants randomized to semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. Liver enzymes were tracked as a secondary or exploratory measure in the STEP program, and the pattern reported in the literature is that ALT tends to move in the same direction as weight loss and improves more in people who lose more weight [1]. The specific magnitude of ALT change often cited for STEP-1 (commonly stated as roughly 10 to 20% from baseline) has not been independently verified against the primary trial report or its supplementary appendix for this article, and should be confirmed by a reviewer with access to that data before being published as a fixed figure.

A follow-up analysis of the STEP-1 extension followed participants after treatment stopped and found that most regained a substantial portion of lost weight, with reversal of metabolic improvements that had accompanied weight loss [2]. This is the strongest evidence in the source set that any ALT benefit is tied to continued weight loss, not a lasting drug effect.

Separately, a liver fat imaging substudy in people with MASLD reported a large relative reduction in liver fat content with semaglutide 2.4 mg compared to placebo [3]. This trial is a better direct source for liver-specific claims than STEP-1, because it specifically measured hepatic fat rather than treating it as a secondary observation. The exact percentage reduction should be confirmed against the primary Lancet publication before being restated as a specific number in patient-facing material.

The strongest liver-specific evidence in this set is the phase 2 semaglutide MASH trial (N=320), which found that semaglutide 0.4 mg daily (roughly equivalent in exposure to 2.4 mg weekly) produced resolution of steatohepatitis without worsening fibrosis in 59% of treated patients versus 17% on placebo at 72 weeks, with ALT normalization more common in the treatment arm [4]. This is a trial designed and powered around liver histology, which makes it more directly relevant to hepatic claims than a weight-loss trial reporting ALT as a side observation.

Why ALT tends to fall

Two mechanisms plausibly explain the pattern, and they are not mutually exclusive.

Weight loss reduces triglyceride accumulation in hepatocytes (steatosis), which is a known driver of low-grade hepatocellular injury and chronic ALT elevation. As liver fat clears, ALT leakage into the bloodstream falls. This is the most straightforward and best-supported mechanism, consistent with the liver fat imaging substudy above [3].

Independent of weight loss, GLP-1 receptor agonism has been linked in mechanistic studies to reduced hepatic lipogenesis and improved insulin sensitivity, both of which could lower fat accumulation even before major weight change occurs [5]. A separate line of animal-model evidence found that GLP-1 analogs, including semaglutide, reduced inflammatory markers in a mouse atherosclerosis model [6]; this supports a plausible anti-inflammatory pathway but was not a liver-specific or human study, so it should be read as mechanistic support rather than direct evidence of a hepatic anti-inflammatory effect in people.

Decision framework: what to do with an ALT change on Wegovy

This is a practical framework for interpreting an ALT result during Wegovy treatment. It is not a substitute for individualized clinical judgment, and any dosing or treatment decision should be made with the prescribing clinician.

The unifying rule: ALT direction on Wegovy should track weight and liver fat trend. When it does not, or when it rises sharply, the cause is more likely gallbladder disease, dehydration, a drug interaction, or an unrelated liver process than a direct toxic effect of semaglutide, and it deserves a workup rather than reassurance or automatic discontinuation.

When ALT can rise instead of fall

Gallbladder disease is the most clinically significant cause of ALT elevation during Wegovy treatment. Rapid weight loss increases the likelihood of gallstone formation, and STEP-1 reported cholelithiasis in a small but consistently higher proportion of semaglutide-treated participants than placebo participants [1]. The FDA prescribing information for Wegovy as of its 2021 label instructs counseling patients on gallstone symptoms including right upper quadrant pain, nausea after fatty meals, and jaundice [7]. Acute cholecystitis or bile duct obstruction can produce ALT elevations well above normal and needs urgent evaluation, not routine follow-up.

Gastrointestinal side effects severe enough to cause dehydration can also produce mild, transient ALT elevation, typically resolving with hydration and symptom management rather than dose changes.

In people with pre-existing MASLD or MASH, ALT can fluctuate during the first months of treatment even as liver fat is decreasing, a pattern sometimes described as lipid mobilization. A Cochrane-indexed review of GLP-1 agonists in fatty liver disease is listed as source material for this claim, but the specific conclusion that "early ALT variability does not predict poor outcomes" should be verified against the completed review text before being restated as an established finding [8].

Because semaglutide delays gastric emptying, it can alter the absorption timing of other medications, including some with hepatotoxic potential. A new ALT rise in someone who recently started another medication alongside Wegovy should prompt a medication review before the change is attributed to semaglutide.

Monitoring: a reasonable approach, not a fixed protocol

Checking ALT before starting Wegovy is reasonable practice, both to catch undiagnosed MASLD and to establish a baseline for interpreting later results. The American Association for the Study of Liver Diseases (AASLD)-led multisociety consensus statement established updated terminology for fatty liver disease, replacing "NAFLD" and "NASH" with MASLD and MASH; it is a naming and diagnostic-criteria document rather than a treatment or screening-frequency guideline, so it should not be cited as the source for a specific screening schedule [9].

A commonly used monitoring pattern in clinical practice, offered here as site judgment rather than a guideline mandate, is: baseline liver panel before the first dose, a repeat check around month 3, another around month 6, and a full hepatic panel at month 12, with annual checks thereafter if values are stable. People with known MASLD or MASH are often monitored more frequently in the first year. The Endocrine Society's clinical practice guideline on obesity pharmacotherapy addresses hepatic monitoring considerations for patients with pre-existing liver disease starting GLP-1 therapy; the exact wording of its recommendation should be confirmed directly from the guideline rather than from a paraphrase, since no verbatim quotation from it could be verified for this draft [10].

A mild, isolated ALT elevation, on the order of 1.5 times the upper limit of normal, in someone with no symptoms and a recent start date, is reasonably managed with a repeat check in 4 to 6 weeks rather than immediate discontinuation. An ALT elevation above roughly 3 times the upper limit of normal, or any elevation accompanied by right upper quadrant pain, jaundice, or dark urine, warrants prompt evaluation.

How Wegovy compares with other GLP-1 agonists on liver enzymes

Semaglutide 2.4 mg is not the only GLP-1 receptor agonist studied for liver effects. Liraglutide 3.0 mg (marketed for weight management as Saxenda) was studied earlier and at a lower dose specifically in NASH: the LEAN trial (N=52) found that liraglutide 1.8 mg resolved steatohepatitis in 39% of patients versus 9% on placebo over 48 weeks [11]. Liraglutide's average weight loss (roughly 5 to 8%) is lower than semaglutide's, and its liver benefit was correspondingly smaller in this trial.

Tirzepatide (marketed for weight management as Zepbound), a dual GIP/GLP-1 receptor agonist, produced greater average weight loss than semaglutide 2.4 mg in its pivotal trial, up to 22.5% at the highest dose in SURMOUNT-1 [12]. Whether this translates into a proportionally larger ALT benefit has not been established by a head-to-head hepatic outcome trial in the sources available here, and should be treated as a plausible inference from weight loss magnitude rather than a demonstrated comparative result.

The reasonable working assumption, supported indirectly by the pattern across these trials, is that ALT improvement tracks weight loss magnitude across the GLP-1 and GIP/GLP-1 drug class, rather than being a unique property of any single molecule. This should not be read as a formal comparative claim, since no trial in the source set directly compared hepatic outcomes between semaglutide and tirzepatide.

Why this matters for MASLD and MASH

Fatty liver disease is common; a widely cited global epidemiology analysis estimated that roughly a quarter of adults worldwide have some form of it, with a meaningful subset progressing toward steatohepatitis and, over years, cirrhosis risk [13]. ALT is an accessible, if imperfect, marker of liver injury, and it is not a direct measure of fibrosis stage.

The phase 2 MASH trial described above found MASH resolution without fibrosis worsening in 59% of semaglutide-treated patients versus 17% on placebo, with ALT normalization more common in the treatment group [4]. A phase 3 trial (ESSENCE) is evaluating semaglutide 2.4 mg specifically in people with MASH and stage F2 to F3 fibrosis [14]; any claim about presented or interim results from this trial should be checked against its primary publication, since conference-reported interim data can change before formal peer-reviewed publication.

For a patient with obesity, an elevated ALT, and ultrasound-confirmed steatosis who is already losing weight and improving on Wegovy, an immediate separate liver-directed therapy or hepatology referral is not automatically necessary, but this depends heavily on fibrosis stage rather than ALT trend alone. People with higher-risk fibrosis markers (based on tools like FIB-4 or elastography, with specific numeric cutoffs varying by guideline and best confirmed with a hepatologist) generally warrant ongoing liver-specific follow-up regardless of how ALT is trending on Wegovy, because ALT can normalize while fibrosis remains unchanged.

What happens to ALT if Wegovy is stopped

Discontinuing semaglutide is associated with substantial weight regain in most people, and the STEP-1 extension analysis found reversal of associated metabolic improvements, which is consistent with ALT rising back toward pre-treatment levels as liver fat reaccumulates [2]. This is the clearest evidence in the source set that any ALT benefit depends on continued treatment rather than a lasting drug effect. It is a reasonable inference, not a directly measured re-elevation of ALT specifically, since the cited analysis focused on weight and broader metabolic markers.

People with MASLD or MASH who normalize ALT on Wegovy and consider stopping should discuss a monitoring plan with their prescriber, including when to recheck labs and what threshold of ALT re-elevation or weight regain would prompt restarting therapy or considering an alternative agent.

Evidence boundary

Established: semaglutide 2.4 mg produces substantial weight loss in trials, and a dedicated MASH trial found significant histologic and enzyme improvement compared to placebo. Liver fat reduction has been directly measured in an imaging substudy. Gallstone disease is a recognized, labeled risk of rapid weight loss on this drug.

Plausible but not confirmed here: a specific percentage ALT reduction for the general Wegovy population beyond the dedicated MASH and imaging trials; a direct hepatic advantage of tirzepatide over semaglutide based on comparative weight loss; the specific conclusion that early ALT variability on GLP-1 therapy does not predict long-term outcomes.

Not established: that Wegovy can replace fibrosis-specific therapy in people with advanced fibrosis; that ALT trend alone can substitute for fibrosis staging; a fixed, universal monitoring schedule endorsed by a single regulatory body specifically for ALT during Wegovy treatment.